Top of this page
Skip navigation, go straight to the content

Newsroom January 2016

Briviact®

In Europe, Briviact® (brivaracetam) is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.

 


January, 2016

Briviact EU

In Focus archive